EGL Genetics Expands Its International Footprint

Published on 09/05/13

EGL Genetics and Genomi-k to Provide Expanded Genetic Testing Options in Mexico

ATLANTA -- EGL Genetics (EGL) and Genomi-k recently formed a partnership to expand genetic testing options for citizens of Mexico. EGL will be performing confirmatory testing for Genomi-k expanded newborn screening and will additionally support Genomi-k with molecular testing.

Genomi-k, founded in 2007 and based out of Monterrey, Mexico, offers three main services: expanded newborn screening (ENS), auditory brainstem response (ABR) hearing screening, and genetic testing. It is the current market leader for ENS and ABR hearing screening in Mexico, with operations in 29 Mexican states. Genomi-k is also the only company in Mexico currently screening for Severe Combined Immunodeficiency (SCID) and lysosomal storage disorders. Convinced of the importance of genetic testing to the development of Mexico, Genomi-k focuses many resources towards educating physicians on the importance of genetic testing to improve clinical diagnoses.

EGL is an academic, not-for-profit organization and a global leader in genetic testing. Associated with the prestigious Emory University School of Medicine, EGL has fully integrated biochemical, cytogenetics, and molecular laboratories, employing the latest technologies, including next generation sequencing and whole exome sequencing, for some of the most comprehensive genetic testing available. EGL is the first clinical laboratory to contribute to the “Free the data” movement, by giving the clinical and research community open-access to its online variant database, EmVClass, with no registration required. EGL also serves as the follow-up laboratory for the state of Georgia Newborn Screening Program, making it the perfect partner for Genomi-k and its ENS program.

EGL Executive Director, Madhuri Hegde, PhD, FACMG, relays the importance of building international relationships throughout the global genetic community in saying, “As more genetic data becomes available, it becomes increasingly more important to share it with the global community. The EGL mission has always been focused on improving patient care by facilitating this information exchange and we believe our new partnership with Genomi-k will not only improve clinical diagnoses in Mexico, but also contribute significantly back to the scientific medical community.” Genomi-k is one of several international relationships being strengthened by EGL.

For more information on the over 800 genetic tests offered by EGL, including its next generation sequencing panels and whole exome sequencing, please visit www.geneticslab.emory.edu or call 404-778-8499.

New and Updated Gene Panels

Industry-leading number of gene panels

EGL Next Generation Sequencing Panels include comprehensive, evidence-based gene lists, improved turnaround times, and reduced pricing.